About this episode

This episode reviews the RASolute 302 trial and its implications for treating metastatic pancreatic adenocarcinoma.

Two Onc Docs , hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air ® partnered with Two Onc Docs to provide a comprehensive review of data from the phase 3 RASolute 302 trial (NCT06625320), a landmark study presented at the 2026 ASCO Annual Meeting that has established daraxonrasib (RMC-6236) as the new standard of care (SOC) for the second-line treatment of patients with metastatic pancreatic adenocarcinoma. The discussion began by highlighting the historical context of second-line treatment, where standard chemotherapy options like FOLFOX (leucovorin calcium, fluorouracil, and oxaliplatin) or gemcitabine-based regimens typically yielded a median overall survival (OS) of only approximately 6 to 7 months. Although RAS…

More episodes of OncLive® On Air

• S17 Ep32: Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD · June 10, 2026 · 10 min

Explore listener stats, chart rankings, contacts and more on the OncLive® On Air podcast page.